Announcement • Aug 06
Appili Therapeutics Inc. and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine
Appili Therapeutics Inc. announced a new publication in the journal Vaccine, supporting the efficacy of its biodefense vaccine candidate, ATI-1701. The manuscript, titled, "Vaccination with a novel live attenuated strain of Francisella tularensis subsp. tularensis protects cynomolgus macaques against aerosol F. tularensis infection," details studies showing robust and durable protection from lethal tularemia exposure in both rat and non-human primate models. ATI-1701, a live attenuated strain of F. tularensis, is being developed as a first-in-class vaccine to protect against tularemia, a highly contagious and potentially fatal bacterial disease. The publication, co-authored by Dr. Carl Gelhaus, Director of Non-Clinical Research at Appili, and researchers from leading biodefense institutions in the U.S., Canada, and Sweden, highlights key findings from multiple preclinical studies. Key results from the study include: 100% survival in rats challenged with aerosolized SCHU S4 up to one-year post-vaccination, even at challenge doses >10,000x the median lethal dose (LD50). In cynomolgus macaque, ATI-1701 demonstrated up to 100% protection, reduced disease severity, and improved histopathological outcomes. Immunized animals exhibited robust antibody responses, correlating with survival and supporting the vaccine's immunogenic potential. This study reinforces ATI-1701's potential as a leading candidate for tularemia prevention and supports continued development in partnership with the U.S. Department of Defense. ATI-1701 is the Company's first-in-class vaccine candidate for the prevention of infection with F. tularensis. Since it is a highly infectious pathogen capable of causing severe illness, medical countermeasures for F. tularensis are a top biodefense priority for governments around the world. There is currently no approved vaccine for the prevention of tularemia in the United States or other major global markets, strengthening ATI-1701's position as a potentially valuable vaccine urgently needed on the market. About ATI-1701 is a novel, live-attenuated vaccine for F. tularensis, which causes tularemia, a Category A pathogen which can be aerosolized and is over 1,000 times more infectious than anthrax. Since it is a highlyinfect pathogen capable of causing severe illnesses, medical counter measures for F. tularensis is a top biodefense priority For the United States and governments around the world. There are currently no approved vaccine for the prevent of infection of tularemia in theUnited States or other major global markets. There is currently no approved vaccines for the prevention of Tularemia in the United States and other major global markets, strengthen ATI-1701's position As a potentially valuable vaccine urgently needed in the market. About ATI- 1701: ATI-1701 is a new, live-attenuated vaccine For F. tularensis,which causes tularemia, a category A pathogen which can be Aerolized and is over 1.000 times more infectious than anthra. Since it is a highly infection capable of causing severe illness, Medical counter measures for F. tularemia are a top biodefensepriority for the United States and governments around The world. There is currently no approval vaccine for the prevention of tularensis in the United States or other large global markets, strengthening ATI- 1701's position as a potentially significant vaccine urgently needed on the market". About ATI-1701 is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections with unmet needs, Appili's goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel antiparasitic for thetreatment disease, and a novel easy to use, and a novel easy to used, liquid oral formulation targeting parasitic and a novel easy to use.
